103263Centre for Antimicrobial PharmacodynamicsClosedCentresInnovate UKThis investment will enable the formation of a Centre for Antimicrobial Pharmacodynamics that will directly facilitate and accelerate new drug development for AMR. The Centre will be aligned with newly funded accelerators (CARB-X). Antimicrobial pharmacokinetics and pharmacodynamics (PK-PD) is a mandatory regulatory requirement for all anti-infective drug development yet there are few organisations with the experience and insight to undertake these studies. Thus, a Centre will provide a facility for drug development in the UK that is currently missing. The investment will capitalise on existing infrastructure and expertise to a build a state-of-the-art facility for imaging new molecules in tissues, extending in vitro PK-PD models such as hollow fibre infection models, and consolidate advanced PK-PD modelling expertise with parallel computing. The Centre will help develop new drugs for AMR by providing PK-PD packages for new molecules being supported by accelerators in the UK and USA.